NEW YORK, December 05, 2022 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a proposed class action lawsuit against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) in the United States District Court for the Southern District of New York. SPPIThomas J. Riga, the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, Francois J. Lebel, the Company’s Chief Medical Officer, and Nora E. Brennan, the Company’s Chief Financial Officer.

The lawsuit alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder by the SEC and is filed on Plaintiffs on behalf of all filed purchasers of Spectrum common stock during the period from December 6, 2021 through September 22, 2022 (“Class Period”).

If you are a member of the proposed class, you have no later than 60 days from today to request the court to serve as lead plaintiff for the proposed class. You do not have to seek lead plaintiff to participate in a possible recovery.

If you have any questions about this notice, the Complaint, your rights or your interests, or would like a copy of the Complaint, please email Attorneys Jeffrey P. Campisi (jcampisi@kaplanfox.com) or Larry King (lking@kaplanfox.com), or contact them by phone, mail or fax, or click here.

The lawsuit alleges that the defendants were conducting a phase 2 clinical trial called ZENITH20. The ZENITH20 study was an ongoing, multicenter, multicohort-free, activity-estimating study to evaluate the antitumor efficacy, safety, and tolerability of poziotinib or “pozi” in patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring specific mutations ( HER2 exon 20 insertion mutations) and have previously been treated with standard of care. The Complaint further alleges that during the Class Period, the Defendants misrepresented the safety and efficacy data of…